ArticleScientific reports2025
Sida Rhombifolia linn: an empirical analysis on phytochemicals and an in vitro outcome on anti-inflammatory and antioxidant perspective.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sida Rhombifolia Linn (SR) is a drug of importance in Ayurveda, used for the multiple disease therapy. In Ayurvedic Pharmacopeia, it is purported as source of Bala in India. It is reported as a rejuvenator of muscles with therapeutic effects in joint pains, rheumatism and neurological deficits. The study objective was to strengthen the chemosystemics and pharmacology of the genera via detailed phytochemical evaluation and invitro assessment of anti-inflammatory and cytotoxic properties. Preliminary analysis demonstrated presence of compounds like alkaloids, phenolics, flavonoids, etc. The invitro assessment revealed anti-inflammatory effect in real time PCR through gene panel expression of PERK, GRP78, ATF6, IRE1A and CHOP. The cell viability was tuned to concentrations up to 120 µg/ml. Through the phytochemical evaluation studies, the ubiquity of bioactive secondary metabolites with therapeutic functions were confirmed. This propagates the potential to feature as a primary constituent in drug development after further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.